Abstract
Erbin belongs to the LAP protein family. Originally, Erbin was described as a Her2-interacting protein. Recent studies demonstrated that Erbin could inhibit the Ras-mediated activation of the mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB) and transforming growth factor β (TGF-β) signaling pathways. It suggests that Erbin may function as a signaling molecule. The functions of Erbin in determining cell polarity and cell adhesion have been well described. This review mainly focuses on the recent findings in regulation of signaling pathways by Erbin.
Keywords: Erbin, MAPK, ERK, NF-κB, TGF-β, signal transduction, carbonyl termini, epithelial morphogensis, mutagenesis, velocardiofacial syndrome, down regulation
Current Protein & Peptide Science
Title: Erbin, a Negative Regulator in Diverse Signal Pathways
Volume: 11 Issue: 8
Author(s): Dan Liu, Ming Shi, Huijun Duan, Caili Han and Ning Guo
Affiliation:
Keywords: Erbin, MAPK, ERK, NF-κB, TGF-β, signal transduction, carbonyl termini, epithelial morphogensis, mutagenesis, velocardiofacial syndrome, down regulation
Abstract: Erbin belongs to the LAP protein family. Originally, Erbin was described as a Her2-interacting protein. Recent studies demonstrated that Erbin could inhibit the Ras-mediated activation of the mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB) and transforming growth factor β (TGF-β) signaling pathways. It suggests that Erbin may function as a signaling molecule. The functions of Erbin in determining cell polarity and cell adhesion have been well described. This review mainly focuses on the recent findings in regulation of signaling pathways by Erbin.
Export Options
About this article
Cite this article as:
Liu Dan, Shi Ming, Duan Huijun, Han Caili and Guo Ning, Erbin, a Negative Regulator in Diverse Signal Pathways, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557673
DOI https://dx.doi.org/10.2174/138920310794557673 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy PAI-1 - A Potential Therapeutic Target in Cancer
Current Drug Targets Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma
Protein & Peptide Letters Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Needle in a Haystack: Targeting Specific Glucuronidases Amid the Human Microbiome
Current Enzyme Inhibition Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer “The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease”
Current Clinical Pharmacology Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Safety of Technosphere Inhaled Insulin
Current Drug Safety Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Induction of Senescent-Like Growth Arrest as a New Target in Anticancer Treatment
Current Cancer Drug Targets Natural and Synthetic Furanocoumarins as Treatment for Vitiligo and Psoriasis
Current Drug Therapy Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Mini-Reviews in Medicinal Chemistry